German drug discovery and contract services firm Evotec announced a sweeping restructuring that will cut roughly one‑sixth of its workforce—about 800 people—and close four additional sites as part of a multi‑year transformation. Management framed the actions as necessary to refocus operations and improve financial sustainability. The company said the layoffs follow prior reductions and are intended to rationalize global capacity amid changing client demand. Evotec indicated the restructuring will affect discovery, manufacturing and corporate roles, and that remaining operations will be consolidated to prioritize core assets. The move underscores pressures on integrated service providers to align capacity with client pipelines and the volatility facing CDMOs and discovery platforms as biopharma reprioritizes outsourcing strategies.